
Jager-van Dijk is new Arletta Pharma Solutions CEO
Brian Attwood | October 13, 2026 | Appointment | | FDA, Female Sexual Disorders, Genito-Urinary system, HRT, Obstetrics & Gynaecology, specialty pharmaceuticals, women’s health
Netherlands-based clinical-stage biopharmaceutical company developing innovative therapies for women with Female Sexual Disorders (FSD), Arletta Pharma Solutions has appointed Jeannette Jager-van Dijk as Chief Executive Officer. The global pharmaceutical executive has more than three decades of leadership experience in women’s health, vaccines and specialty pharmaceuticals, including U.S.-based responsibility for the development, registration and commercialization of women’s health products.
Arletta recently received written feedback from the U.S. Food and Drug Administration (FDA) on the proposed design of MONARCH, its planned U.S. Phase 2 study of Lybrido, the Arletta’s lead investigational on-demand, dual-action therapy for women with Female Sexual Interest/Arousal Disorder (FSIAD) and Hypoactive Sexual Desire Disorder (HSDD). The Agency supported core elements of the proposed study design and provided guidance relevant to the potential future development pathway for Lybrido™.
Related Content

FDA grants De Novo authorisation to light-filtering device for migraine
The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …

EndoCyclic New Drug application approved by US FDA for endometriosis treatment
EndoCyclic Therapeutics’ Investigational New Drug (IND) application for its lead programme, ENDO-205, has been approved …

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …






